The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Induction of CD4+CD25+regulatory T cells by copolymer-I through activation of transcription factor Foxp3
Open accessAbstract
Copolymer-I (COP-I) has unique immune regulatory properties and is a treatment option for multiple sclerosis (MS). This study revealed that COP-I induced the conversion of peripheral CD4+CD25-to CD4+CD25+regulatory T cells through the activation of transcription factor Foxp3. COP-I treatment led to a significant increase in Foxp3 expression in CD4+T cells in MS patients whose Foxp3 expression was reduced at baseline. CD4+CD25+T cell lines generated by COP-I expressed high levels of Foxp3 that correlated with an increased regulatory potential. Furthermore, we demonstrated that the induction of Foxp3 in CD4+T cells by COP-I was mediated through its ability to produce IFN-γ and, to a lesser degree, TGF-β1, as shown by antibody blocking and direct cytokine induction of Foxp3 expression in T cells. It was evident that in vitro treatment and administration with COP-I significantly raised the level of Foxp3 expression in CD4+T cells and promoted conversion of CD4+CD25+regulatory T cells in wild-type B6 mice but not in IFN-γ knockout mice. This study provides evidence for the role and mechanism of action of COP-I in the induction of CD4+CD25+regulatory T cells in general and its relevance to the treatment of MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,699
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
Self-citationAn essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark, L. B., Yasayko, S.-A., Wilkinson, J. E., Galas, D., Ziegler, S. F., & Ramsdell, F. (2001) · Nature Genetics · doi:10.1038/83784 · Cited by 2,636
Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis
Viglietta, V., Baecher-Allan, C., Weiner, H. L., & Hafler, D. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031579 · Cited by 1,856
Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25– T cells
R.Walker, M., Kasprowicz, D. J., Gersuk, V. H., Bènard, A., Van Landeghen, M., Buckner, J. H., & Ziegler, S. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19441 · Cited by 1,245
Fantini, M. C., Becker, C., Monteleone, G., Pallone, F., Galle, P. R., & Neurath, M. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5149 · Cited by 1,135
Comi, G., Filippi, M., & Wolinsky, J. S. (2001) · PubMed · Cited by 688
Comi, G., Filippi, M., Wolinsky, J. S., & European/Canadian Glatiramer Acetate Study Group (2001) · Annals of Neurology · doi:10.1002/ana.64 · Cited by 650
Multiple immuno-regulatory defects in type-1 diabetes
Kukreja, A., Cost, G., Marker, J., Zhang, C., Sun, Z., Lin‐Su, K., Ten, S., Sanz, M. M., Exley, M. A., Wilson, B., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci13605 · Cited by 640
Multiple immuno-regulatory defects in type-1 diabetes
Kukreja, A., Cost, G., Marker, J., Zhang, C., Sun, Z., Lin-Su, K., Ten, S., Sanz, M., Exley, M., Wilson, B., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213605 · Cited by 566
Scurfin (FOXP3) Acts as a Repressor of Transcription and Regulates T Cell Activation
Schubert, L. A., Jeffery, E., Zhang, Y., Ramsdell, F., & Ziegler, S. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104521200 · Cited by 548
A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple Sclerosis
Bornstein, M. B., Miller, A., Slagle, S., Weitzman, M., Crystal, H., Drexler, E., Keilson, M., Merriam, A., Wassertheil-Smoller, S., Spada, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708133170703 · Cited by 462
Lafaille, J. J., Keere, F. V. D., Hsu, A. L., Baron, J. L., Haas, W., Raine, C. S., & Tonegawa, S. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.2.307 · Cited by 426
Duda, P. W., Schmied, M. C., Cook, S. L., Krieger, J. I., & Hafler, D. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8970 · Cited by 416
Neuhaus, O., Farina, C., Yassouridis, A., Wiendl, H., Then Bergh, F., Dose, T., Wekerle, H., & Hohlfeld, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7452 · Cited by 299
Ziemssen, T. (2002) · Brain · doi:10.1093/brain/awf252 · Cited by 268
Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis
Moreau, T., Coles, A., Wing, M., Isaacs, J., Hale, G., Waldmann, H., & Compston, A. (1996) · Brain · doi:10.1093/brain/119.1.225 · Cited by 250
Mechanisms of action of glatiramer acetate in multiple sclerosis
Neuhaus, O., Farina, C., Wekerle, H., & Hohlfeld, R. (2001) · Neurology · doi:10.1212/wnl.56.6.702 · Cited by 248
Fridkis-Hareli, M., Teitelbaum, D., Gurevich, E., Pecht, I., Brautbar, C., Kwon, O. J., Brenner, T., Arnon, R., & Sela, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4872 · Cited by 243
Waisman, A., Ruiz, P. J., Hirschberg, D. L., Gelman, A., Oksenberg, J. R., Brocke, S., Mor, F., Cohen, I. R., & Steinman, L. (1996) · Nature Medicine · doi:10.1038/nm0896-899 · Cited by 237
Miller, A., Shapiro, S., Gershtein, R., Kinarty, A., Rawashdeh, H., Honigman, S., & Lahat, N. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00191-x · Cited by 225
Aharoni, R., Teitelbaum, D., Sela, M., & Arnon, R. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00166-0 · Cited by 173
Mechanisms of immunomodulation by glatiramer acetate
Gran, B., Tranquill, L. R., Chen, M., Bielekova, B., Zhou, W., Dhib–Jalbut, S., & Martin, R. (2000) · Neurology · doi:10.1212/wnl.55.11.1704 · Cited by 158
Teitelbaum, D., Fridkis‐Hareli, M., Arnon, R., & Sela, M. (1996) · Journal of Neuroimmunology · doi:10.1016/0165-5728(95)00180-8 · Cited by 153
Impaired Development of CD4+ CD25+ Regulatory T Cells in the Absence of STAT1
Nishibori, T., Tanabe, Y., Su, L., & David, M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20020509 · Cited by 139
Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.
Teitelbaum, D., Milo, R., Arnon, R., & Sela, M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.1.137 · Cited by 112
Farina, C. (2001) · Brain · doi:10.1093/brain/124.4.705 · Cited by 112
Chen, M., Gran, B., Costello, K., Johnson, K. P., Martinꝉ, R., & Dhib-Jalbut, S. S. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700401 · Cited by 106
Ben‐Nun, A., Mendel, I., Bakimer, R., Fridkis‐Hareli, M., Teitelbaum, D., Arnon, R., Sela, M., & de Rosbo, N. K. (1996) · Journal of Neurology · doi:10.1007/bf00873697 · Cited by 105
Racke, M. K., Martinꝉ, R., McFarland, H. F., & Fritz, R. B. (1992) · Journal of Neuroimmunology · doi:10.1016/0165-5728(92)90157-g · Cited by 80
Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis
Hong, J., Zang, Y. C. Q., Hutton, G. J., Rivera, V. M., & Zhang, J. Z. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.03.004 · Cited by 68
Self-citationBrod, S. A., Nelson, L. D., Khan, M., & Wolinsky, J. S. (1997) · International Journal of Neuroscience · doi:10.3109/00207459709000638 · Cited by 18
Role of Magnetic Resonance Imaging and Immunotherapy in Treating Multiple Sclerosis
Zhang, J., & Hutton, G. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104739 · Cited by 18
Self-citationBarth, H., Klein, K., Börtlein, A., et al. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00355-7 · Cited by 16
Cited by
T cells in multiple sclerosis and experimental autoimmune encephalomyelitis
Fletcher, J. M., Lalor, S. J., Sweeney, C. M., Tubridy, N., & Mills, K. H. G. (2010) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2010.04143.x · Cited by 945
Baruch, K., Rosenzweig, N., Kertser, A., Deczkowska, A., Sharif, A. M., Spinrad, A., Tsitsou-Kampeli, A., Sarel, A., Cahalon, L., & Schwartz, M. (2015) · Nature Communications · doi:10.1038/ncomms8967 · Cited by 491
Type II monocytes modulate T cell–mediated central nervous system autoimmune disease
Weber, M. S., Prod'homme, T., Youssef, S., Dunn, S. E., Rundle, C. D., Lee, L., Patarroyo, J. C., Stüve, O., Sobel, R. A., Steinman, L., et al. (2007) · Nature Medicine · doi:10.1038/nm1620 · Cited by 447
Oxidative Stress and the Pathogenesis of Neurodegenerative Disorders
Reynolds, A., Laurie, C., Lee Mosley, R., & Gendelman, H. E. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(07)82016-2 · Cited by 432
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E., & Lee Mosley, R. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0507296 · Cited by 420
Metadata
- Authors
- Hong, J., Li, N., Zhang, X., Zheng, B., & Zhang, J. Z.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-04-25
- Volume
- 102
- Issue
- 18
- Pages
- 6449-6454
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2024152763
- Cited by
- 264
- References
- 37
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.